BillionToOne, Inc. (BLLN)
| Market Cap | 5.07B |
| Revenue (ttm) | 209.03M |
| Net Income (ttm) | -30.62M |
| Shares Out | 45.40M |
| EPS (ttm) | -2.99 |
| PE Ratio | n/a |
| Forward PE | 500.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,946 |
| Open | 105.13 |
| Previous Close | 104.02 |
| Day's Range | 104.03 - 118.00 |
| 52-Week Range | 88.00 - 138.70 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 138.67 (+24.21%) |
| Earnings Date | Dec 9, 2025 |
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and type... [Read more]
Analyst Forecast
According to 6 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $138.67, which is an increase of 24.21% from the latest price.
News
BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025
MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all...
Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally
BillionToOne, Inc., (NASDAQ: BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million.
BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests
Wall Street analysts, who acted as lead underwriters for BillionToOne's Nasdaq debut last month, began coverage of the diagnostics firm on Monday with broadly upbeat views, pointing to its advanced te...
BillionToOne: A Deserved Opening Day Boom
BillionToOne leverages groundbreaking molecular diagnostics technology, targeting massive prenatal and oncology testing markets with rapid revenue growth. Revenues more than doubled to $152 million in...
Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering
REDWOOD CITY, Calif. , Nov. 6, 2025 /PRNewswire/ -- Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a leading law firm in technology and life sciences transactions, represented long-tim...
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Shares of BillionToOne rose 66.67% in their Nasdaq debut on Thursday, valuing the molecular diagnostics firm at $4.4 billion.
Molecular diagnostics firm BillionToOne raises $273 million in US IPO
Molecular diagnostics firm BillionToOne raised $273.1 million in its U.S. initial public offering on Wednesday, pricing its shares above its marketed range.
BillionToOne Announces Pricing of Upsized Initial Public Offering
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all...
BillionToOne Announces Launch of Initial Public Offering Roadshow
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announc...
BillionToOne targets over $2 billion valuation in US IPO
Molecular diagnostics firm BillionToOne said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.
BillionToOne Launches IPO In Slowing IPO Market
BillionToOne, Inc. is rapidly growing in the prenatal and oncology diagnostics sectors, nearing operating breakeven, and has filed for a $100 million IPO. BLLN's revenue is driven mainly by its UNITY ...
U.S. IPO Weekly Recap: 6 IPOs Debut, Pipeline Grows, Despite Government Shutdown
Six IPOs debuted this week, while two SPACs listed. Thirteen IPOs and five SPACs also submitted initial filings. No traditional IPOs are currently scheduled for the week ahead as the government shutdo...
Molecular diagnostics firm BillionToOne files for US IPO
BillionToOne filed for an initial public offering in the United States on Tuesday.
BillionToOne IPO Registration Document (S-1)
BillionToOne has filed to go public with an IPO on the NASDAQ.